Back
Maravai LifeSciences
Life sciences company providing critical products to enable the development of drug therapies
Company website ↗About
Total Funding
$1B
Maravai LifeSciences was formed in March 2014 as a partnership among Carl Hull and Eric Tardif -- proven leaders in the life sciences industry -- and GTCR, a leading private equity firm. Maravai’s mission is to build a transformative life sciences products company by acquiring outstanding businesses and accelerating their growth. They do this through direct cash investments in their existing operations, by acquiring complementary businesses or product lines and by contributing our proven operating expertise.
Number of employees
51-100
Headquarters
San Diego, California, United States
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.